T-705

T-705 is an antiviral agent that inhibits influenza A, B, and C (IC₅₀s = 0.013-0.48 µg/ml) without inducing cytotoxicity up to 1,000 µg/ml.¹ It inhibits a neuraminidase-resistant influenza strain (GS4071-resistant; IC₅₀ = 0.095 µg/ml) and RNA viruses (IC₅₀s = 4.8-41 µg/ml) but not DNA viruses at concentrations greater than 100 µg/ml. It is active against a variety of viruses, including bunyavirus, arenavirus, and West Nile virus in vitro and in vivo in mice.² T-705 undergoes phosphoribosylation to form T-705-RTP, which inhibits RNA-dependent RNA polymerase (RdRp) in RNA viruses.³ In mice infected with influenza virus, T-705 (200 mg/kg once daily) decreases the rate of mortality and reduces the lung virus yield in a dose-dependent manner at doses ranging from 50-200 mg/kg per day.

WARNING This product is not for human or veterinary use.

1. Furuta, Y., Takahashi, K., Fukuda, Y., et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents and Chemother. 46(4), 977-981 (2002).

2. Furuta, Y., Takahashi, K., Shiraki, K., et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82(3), 95-102 (2009).

3. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents and Chemother. 49(3), 981-986 (2005).